Kidney as a Target Organ in Cardiac Oncology
https://doi.org/10.25207/1608-6228-2020-27-3-92-104
Abstract
The review addresses the problem of kidney lesions in patients with cardiovascular and oncological diseases. In the context of the current spread of cardiovascular and oncological pathologies, a growing number of patients reveal comorbid and/or polymorbid renal dysfunctions. In confluence with cardiovascular disorders, kidney lesions are manifested in various types of the cardiorenal syndrome. In current knowledge, the heart and kidneys are highly interdependent and interact across several interfaces in a complex feedback system. The kidneys can both play a target role and back-influence cardiac functions and pathology. Evidently, the development of acute kidney lesions and / or chronic renal dysfunctions worsens the prognosis of the primary disease and elevates risks of developing acute cardiovascular disorders. Combined cardiovascular and oncological pathologies are nowadays more common. Numerous patients with malignant neoplasms develop renal pathologies due to tumour infiltration or exposure to tumour metabolites, as well as indirectly through the nephrotoxic effect of antitumour chemotherapy and/or radiation therapy. Many studies show that acute kidney lesions and/or chronic renal disorders contribute independently to the severity of cancer and mortality rate. In recent decades, the level of serum creatinine is used as a marker of acute kidney damage, which although harbours inherent weaknesses of being responsive to a spectrum of renal and extra-renal factors and having a delay of 48–72 h of elevation in the blood after exposure to the trigging factor. In this respect, the development of novel kidney-specific lesion biomarkers continues. Among such candidate agents is the kidney injury molecule KIM-1.
About the Authors
Z. D. Mikhailova
City Clinical Hospital No. 38
Russian Federation
Russian Federation
Zinaida D. Mikhailova — Dr. Sci. (Med.), Assoc. Prof., Consulting Physician
Chernyshevskogo str., 22, Nizhny Novgorod, 603000
D. V. Pivovarov
City Clinical Hospital No. 38
Russian Federation
Russian Federation
Dmitrii V. Pivovarov — Physician
Chernyshevskogo str., 22, Nizhny Novgorod, 603000
A. R. Pivovarova
Izhevsk State Medical Academy
Russian Federation
Russian Federation
Al’mira R. Pivovarova — Graduate Student (6th year), Department of General Medicine
Kommunarov str., 281, Izhevsk, 426034
References
1. Cardiology: national leadership. Shlyakhto E.V., editor. Moscow: GEOTAR-Media; 2015. 800 p. (In Russ.).
2. Abuzarova G.R. Cancer pain: facets of a problem. Meditsinskiy sovet = Medical Council. 2018; 10: 97– 100 (In Russ., English abstract). DOI: 10.21518/2079-701X-2018-10-97-100
3. Mortality, Cardiovascular Wu Y., Wang W., Liu T., Zhang D. Association of grip strength with risk of allcause mortality, cardiovascular diseases, and cancer in community-dwelling populations: A meta-analysis of prospective cohort studies. J. Am. Med. Dir. Assoc. 2017; 18(6): 551.e17–551.e35. DOI: 10.1016/j.jamda.2017.03.011
4. Koene R.J., Prizment A.E., Blaes A., Konety S.H. Shared risk factors in cardiovascular disease and cancer. Circulation. 2016; 133(11): 1104–1114. DOI: 10.1161/CIRCULATIONAHA.115.020406
5. The state of cancer care the population of Russia in 2018. Kaprin A.D., Starinsky V.V., Petrov G.V., editors. Мoscow: MNIOI im. P.A. Gertsena — fi lial FGBU “NMITs radiologii” Minzdrava Rossii; 2019. 236 p. (In Russ.).
6. Budanova D.A., Belenkov Y.N., Sokolova I.Y., Antyufeeva O.N., Ershov V.I., Ilgisonis I.S., Gadaev I.Y. The Role of Endothelial Dysfunction in the Development of Cardiotoxic Action of Cytostatics in Patients with Lymphoproliferative Diseases. Kardiologiia. 2019; 59(4): 64–66 (In Russ., English abstract). DOI: 10.18087/cardio.2019.4.10251
7. Strongman H., Gadd S., Matthews A., Mansfi eld K.E., Stanway S., Lyon A.R., et al. Medium and long-term risks of specifi c cardiovascular diseases in survivors of 20 adult cancers: a population-based cohort study using multiple linked UK electronic health records databases. Lancet. 2019; 394(10203): 1041–1054. DOI: 10.1016/S0140-6736(19)31674-5
8. Plokhova E.V., Dundua D.P. Thrombosis in patients with malignancy. Kardiologiia. 2018; 58(9S): 19–28 (In Russ., English abstract). DOI: 10.18087/cardio.2523
9. Iannaccone M., D’Ascenzo F., Vadalà P., Wilton S.B., Noussan P., Colombo F., et al. Prevalence and outcome of patients with cancer and acute coronary syndrome undergoing percutaneous coronary intervention: a BleeMACS substudy. Eur. Heart. J. Acute. Cardiovasc. Care. 2018; 7(7): 631–638. DOI: 10.1177/2048872617706501
10. Ronco C., Haapio M., House A.A., Anavekar N., Bellomo R. Cardiorenal syndrome. J. Am. Coll. Cardiol. 2008; 52(19): 1527–1539. DOI: 10.1016/j.jacc.2008.07.051
11. Wettersten N., Maisel A.S., Cruz D.N. Toward precision medicine in the cardiorenal syndrome. Adv. Chronic. Kidney. Dis. 2018; 25(5): 418–424. DOI: 10.1053/j.ackd.2018.08.017
12. Reznik E.V., Nikitin I.G. Cardiorenal syndrome in patients with chronic heart failure as a stage of the cardiorenal continuum (part i): defi nition, classifi cation, pathogenesis, diagnosis, epidemiology. The Russian Archives of Internal Medicine. 2019; 9(1): 5–22 (In Russ., English abstract). DOI: 10.20514/2226-6704-2019-9-1-5-22
13. Ronco C., Bellasi A, Di Lullo L. Cardiorenal syndrome: an overview. Advances in Chronic Kidney Disease. 2018; 25(5): 382–390. DOI: 10.1053/j.ackd.2018.08.004
14. Sarnak M.J., Amann K., Bangalore S., Cavalcante J.L., Charytan D.M., Craig J.C., et al.; Conference Participants. Chronic Kidney Disease and Coronary Artery Disease: JACC State-of-the-Art Review. J. Am. Coll. Cardiol. 2019; 74(14): 1823–1838. DOI: 10.1016/j.jacc.2019.08.1017
15. Collins A.J., Foley R.N., Gilbertson D.T., Chen S.C. United States renal data system public health surveillance of chronic kidney disease and end-stage renal disease. Kidney. Int. Suppl. 2015; 5(1): 2–7. DOI: 10.1038/kisup.2015.2
16. Mok Y., Ballew S.H., Sang Y., Grams M.E., Coresh J., Evans M., et al. Albuminuria as a Predictor of Cardiovascular Outcomes in Patients With Acute Myocardial Infarction. J. Am. Heart. Assoc. 2019; 8(8):e010546. DOI: 10.1161/JAHA.118.010546
17. Khasanov N.R., Belkorey O.S., Dyakova E.N. Prognostic factors and longterm survival of myocardial infarction patients, complicated by early recurent angina and renal function decrease. Russian Journal of Cardiology. 2016; 3: 66–69 (In Russ., English abstract). DOI: 10.15829/1560-4071-2016-3-66-69
18. Marenzi G., Cosentino N., Bartorelli A.L. Acute kidney injury in patients with acute coronary syndromes. Heart. 2015; 101(22): 1778–1785. DOI: 10.1136/heartjnl-2015-307773
19. Vakulchik K.A., Mezhonov E.M., Vyalkina Yu.A., Shalaev S.V. Acute kidney damage in patients with acute coronary syndrome with ST segment elevation on ECG. Eurasian heart journal. 2017; 3: 42–43 (In Russ.).
20. Bazylev V.V., Gornostaev A.A., Schegol’kov A.A., Bulygin A.V. Frequency risk factors and outcomes acute kidney injury in the early period in patients with chronic kidney disease after cabg surgery. Nephrology (Saint-Petersburg). 2018; 22(4): 96–101 (In Russ., English abstract). DOI: 1561-6274-2018-22-4-96-101
21. Tsai T.T., Patel U.D., Chang T.I., Kennedy K.F., Masoudi F.A., Matheny M.E., et al. Validated contemporary risk model of acute kidney injury in patients undergoing percutaneous coronary interventions: insights from the national cardiovascular data registry Cath-PCI registry. J. Am. Heart. Assoc. 2014; 3(6): e001380. DOI: 10.1161/JAHA.114.001380
22. Mezhonov E.M., Vyalkina Y.A., Vakulchik K.A., Shalaev S.V. Contrast-Induced Acute Renal Injury After Percutaneous Coronary InterventionI in Patients With ST-Segment Elevation Myocardial Infarction. Kardiologiia. 2018; 58(8): 5–11 (In Russ., English abstract). DOI: 10.18087/cardio.2018.8.10157
23. Matějka J., Varvařovský I., Rozsíval V., Herman A., Bláha K., Večeřa J., et al. Heart failure is the strongest predictor of acute kidney injury in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction. Kardiol. Pol. 2016; 74(1): 18–24. DOI: 10.5603/kp.a2015.0115
24. Luboyatnikova E.S., Duplyakov D.V. Acute coronary syndrome in malignancy patients. Russian Journal of Cardiology. 2017; (3): 140–144 (In Russ., English abstract). DOI: 10.15829/1560-4071-2017-3-140-144
25. Kolina I.B., Bobkova I.N. Renal damage with malignant neoplasms. The Clinician. 2014; 8(2): 7–16 (In Russ., English abstract). DOI: 10.17650/1818-8338-2014-2-7-16
26. Klein U., Dalla-Favera R. New insights into the pathogenesis of chronic lymphocytic leukemia. Semin. Cancer. Biol. 2010; 20(6): 377–383. DOI: 10.1016/j.semcancer.2010.10.012
27. Ferlay J., Colombet M., Soerjomataram I., Dyba T., Randi G., Bettio M., et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur. J. Cancer. 2018; 103: 356–387. DOI: 10.1016/j.ejca.2018.07.005
28. Agnello F., Albano D., Micci G., Buono G.D., Agrusa A., Salvaggio G., et al. CT and MR imaging of cystic renal lesions. Insights. Imaging. 2020; 11(1): 5. DOI: 10.1186/s13244-019-0826-3
29. Bach A.G., Behrmann C., Holzhausen H.J., Katzer M., Arnold D., Spielmann R.P., Surov A. Prevalence and patterns of renal involvement in imaging of malignant lymphoproliferative diseases. Acta Radiol. 2012; 53(3): 343–348. DOI: 10.1258/ar.2011.110523
30. Burnasheva E.V., Shatokhin Y.V., Snezhko I.V., Matsuga A.A. Kidney injury in cancer therapy. Nephrology (Saint-Petersburg). 2018; 22(5): 17–24 (In Russ., English abstract). DOI: 10.24884/1561-6274-2018-22-5-17-24
31. Arapova O.I., Rodionov V.V., Shutov A.M. The problem of early diagnosis of acute kidney injury in cancer patients. Ul’yanovskii Mediko-Biologicheskii Zhurnal. 2014; 1: 24–30 (In Russ., English abstract).
32. Gromova E.G., Biryukova L.S., Dzhumabaeva B.T., Kurmukov I.A. Practical recommendations for the correction of nephrotoxicity of anticancer drugs. Zlokachestvennye Opukholi: Prakticheskie Rekomendatsii RUSSCO #3s2. 2017; 7: 540–552 (In Russ.). DOI: 10.18027/2224–5057–2017–7–3s2–540–552
33. Jacob S., Dunn B.L., Qureshi Z.P., Bandarenko N., Kwaan H.C., Pandey D.K., et al. Ticlopidine-, Clopidogrel-, and Prasugrel-Associated thrombotic thrombocytopenic purpura: a 20-year review from the southern network on adverse reactions (SONAR). Semin. Thromb. Hemost. 2012; 38(8): 845–853. DOI: 10.1055/s-0032-1328894
34. Barnett L.M.A., Cummings B.S. Nephrotoxicity and renal pathophysiology: A contemporary perspective. Toxicol. Sci. 2018; 164(2): 379–390. DOI: 10.1093/toxsci/kfy159
35. Nikolaev A.Yu., Ermolenko V.M. Drug-induced acute kidney injury in patients with chronic kidney disease. Nefrologiya i Dializ. 2015; 17(1): 29–33 (In Russ., English abstract).
36. Michalski J.M., Gay H., Jackson A., Tucker S.L., Deasy J.O. Radiation dose-volume effects in radiation-induced rectal injury. Int. J. Radiat. Oncol. Biol. Phys. 2010; 76 (3 Suppl): S123–129. DOI: 10.1016/j.ijrobp.2009.03.078
37. Kala J. Radiation-induced kidney injury. Journal of Onco-Nephrology. 2019; 3(3): 160–167. DOI: 10.1177/2399369319865271
38. Wilhelm-Leen E., Montez-Rath M.E., Chertow G. Estimating the Risk of Radiocontrast-Associated Nephropathy. J. Am. Soc. Nephrol. 2017; 28(2):653–659. DOI: 10.1681/ASN.2016010021
39. Baradaran-Ghahfarokhi M. Radiation-induced kidney injury. J. Ren. Inj. Prev. 2012; 1(2): 49–50. DOI: 10.12861/jrip.2012.17
40. Ikuerowo S.O., Ojewuyi O.O., Omisanjo O.A., Abolarinwa A.A., Bioku M.J., Doherty A.F. Paraneoplastic syndromes and oncological outcomes in renal cancer. Niger. J. Clin. Pract. 2019; 22(9): 1271–1275. DOI: 10.4103/njcp.njcp_35_19
41. Dzhumabaeva B.T., Biryukova L.S. New aspects of pathophysiology and pathomorphology of renal lesions in malignant tumors. Klinicheskaya Onkogematologiya. 2015; 8(4): 390–396 (In Russ., English abstract).
42. Vos J.M., Gustine J., Rennke H.G., Hunter Z., Manning R.J., Dubeau T.E., et al. Renal Disease related to waldenström macroglobulinaemia: incidence, pathology and clinical outcomes. Br. J. Haematol. 2016; 175(4): 623–630. DOI: 10.1111/bjh.14279
43. Motwani S.S., Herlitz L., Monga D., Jhaveri K.D., Lam A.Q., American Society of Nephrology Onco-Nephrology Forum. Paraprotein–related kidney disease: glomerular diseases associated with paraproteinemias. Clin. J. Am. Soc Nephrol. 2016; 11(12): 2260–2272. DOI: 10.2215/CJN.02980316
44. Garces A.H.I., Ang J.E., Ameratunga M., Chénard-Poirier M., Dolling D., Diamantis N., et al. A study of 1088 consecutive cases of electrolyte abnormalities in oncology phase I trials. Eur. J. Cancer. 2018; 104: 32–38. DOI: 10.1016/j.ejca.2018.08.019
45. Oronsky B., Caroen S., Oronsky A., Dobalian V.E., Oronsky N., Lybeck M., et al. Electrolyte disorders with platinum-based chemotherapy: mechanisms, manifestations and management. Cancer. Chemother. Pharmacol. 2017; 80: 895–907. DOI: 10.1007/s00280-017-3392-8
46. O’Donnell E.K., Raje N.S. Myeloma bone disease: pathogenesis and treatment. Clin. Adv. Hematol. Oncol. 2017; 15: 285–295.
47. Foreman J.W. Fanconi Syndrome. Pediatr. Clin. North. Am. 2019; 66(1): 159–167. DOI: 10.1016/j.pcl.2018.09.002
48. Darmon M., Vincent F., Canet E., Mokart D., Pène F., Kouatchet A., et al. Acute kidney injury in critically ill patients with haematological malignancies: results of a multicentre cohort study from the groupe de recherche en réanimation respiratoire en onco-hématologie. Nephrol. Dial. Transplant. 2015; 30(12): 2006–2013. DOI: 10.1093/ndt/gfv372
49. Iff S., Craig J.C., Turner R., Chapman J.R., Wang J.J., Mitchell P., Wong G. Reduced estimated GFR and cancer mortality. Am. J. Kidney. Dis. 2014; 63(1): 23–30. DOI: 10.1053/j.ajkd.2013.07.008
50. Canet E., Zafrani L., Lambert J., Thieblemont C., Galicier L., Schnell D., et al. Acute kidney injury in patients with newly diagnosed high-grade hematological malignancies: impact on remission and survival. PLoS One. 2013; 8(2): e55870. DOI: 10.1371/journal.pone.0055870
51. Smirnov A.V., Rumyantsev A.S. Acute kidney disease. Part I. Nephrology (Saint-Petersburg). 2020; 24(1): 67–95 (In Russ., English abstract). DOI: 10.36485/1561-6274-2020-24-1-67-95
52. Jager K.J., Kovesdy C., Langham R., Rosenberg M., Jha V., Zoccali C. A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases. Kidney. Int. 2019; 96(5): 1048–1050. DOI: 10.1016/j.kint.2019.07.012
53. Garmanova T.N. Genetic causes of congenital diseases of the upper urinary tract. Literature review. Eksperimental’naya i Klinicheskaya Urologiya. 2016; 2: 118–124 (In Russ., English abstract).
54. Goswami S., Pahwa N., Vohra R., Raju B.M. Clinical spectrum of hospital acquired acute kidney injury: A prospective study from Central India. Saudi. J. Kidney. Dis. Transpl. 2018; 29(4): 946–955. DOI: 10.4103/1319-2442.239650
55. Hill N.R., Fatoba S.T., Oke J.L., Hirst J.A., O’Callaghan C.A., Lasserson D.S., Hobbs F.D. Global Prevalence of Chronic Kidney Disease — A Systematic Review and Meta-Analysis. PLoS One. 2016; 11(7): e0158765. DOI: 10.1371/journal.pone.0158765
56. Tomilina N.A., Andrusev A.M., Peregudova N.G., Shinkarev M.B. Renal replacement therapy for End Stage Renal Disease in Russian Federation, 2010— 2015. Russian National Renal Replacement Therapy Registry Report of Russian Public Organization of Nephrologists “Russian Dialysis Society”, Part 1. Nephrology and Dialysis. 2017; 19(S): 1–95 (In Russ.). DOI: 10.28996/1680-4422-2017-4Suppl-1-95
57. Oh D.J. A long journey for acute kidney injury biomarkers. Ren. Fail. 2020; 42(1):154–165. DOI: 10.1080/0886022X.2020.1721300
58. Li W., Yu Y., He H., Chen J., Zhang D. Urinary kidney injury molecule-1 as an early indicator to predict contrast-induced acute kidney injury in patients with diabetes mellitus undergoing percutaneous coronary intervention. Biomed. Rep. 2015; 3(4): 509–512. DOI: 10.3892/br.2015.449
59. Kuzmin O.B., Zhezha V.V., Belaynin V.V., Buchneva N.V., Landar L.N., Serdyuk S.V. Diagnostic and prognostic value of renal tubular injury biomarkers NGAL, KIM-1, L-FABP in chronic kidney disease patients. Nephrology (Saint-Petersburg). 2017; 21(2): 24–32. DOI: 10.24884/1561-6274-2017-21-2-24-32
60. Nikolov G., Boncheva M., Gruev T., Trajkovska K.T., Kostovska I. Urinary biomarkers for follow-up of renal transplantation — Where we are! J. IMAB. 2016; 22(2): 1139–1148. DOI: 10.5272/jimab.2016222.1139
Review
For citations:
Mikhailova Z.D., Pivovarov D.V., Pivovarova A.R. Kidney as a Target Organ in Cardiac Oncology. Kuban Scientific Medical Bulletin. 2020;27(3):92-104. (In Russ.) https://doi.org/10.25207/1608-6228-2020-27-3-92-104
Views:
1171
Email this article 